BioNexus Gene Lab CorpBGLCEarnings & Financial Report
BioNexus Gene Lab Corp is a biotechnology company specializing in molecular diagnostic testing, genetic analysis, and related life science solutions. It caters to healthcare institutions, research organizations, and individual customers, with its primary operational and market focus on the Southeast Asian region.
Revenue
$2.5M
Gross Profit
$309.2K
Operating Profit
$-416.2K
Net Profit
$-348.3K
Gross Margin
12.3%
Operating Margin
-16.5%
Net Margin
-13.8%
YoY Growth
11.0%
EPS
$0.55
BioNexus Gene Lab Corp Q4 FY2024 Financial Summary
BioNexus Gene Lab Corp reported revenue of $2.5M (up 11.0% YoY) for Q4 FY2024, with a net profit of $-348.3K (down 212.9% YoY) (-13.8% margin). Cost of goods sold was $2.2M, operating expenses totaled $725.5K.
Key Financial Metrics
| Total Revenue | $2.5M |
|---|---|
| Net Profit | $-348.3K |
| Gross Margin | 12.3% |
| Operating Margin | -16.5% |
| Report Period | Q4 FY2024 |
BioNexus Gene Lab Corp Annual Revenue by Year
BioNexus Gene Lab Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $7.4M).
| Year | Annual Revenue |
|---|---|
| 2025 | $7.4M |
| 2024 | $9.5M |
| 2023 | $9.8M |
| 2022 | $10.9M |
BioNexus Gene Lab Corp Quarterly Revenue & Net Profit History
BioNexus Gene Lab Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $483.8K | -80.8% | $-1.0M | -214.2% |
| Q3 FY2025 | $2.5M | -3.3% | $-709.0K | -27.9% |
| Q2 FY2025 | $2.3M | +14.5% | $-616.2K | -27.3% |
| Q1 FY2025 | $2.1M | -10.3% | $-623.3K | -29.2% |
| Q4 FY2024 | $2.5M | +11.0% | $-348.3K | -13.8% |
| Q3 FY2024 | $2.6M | +3.0% | $-1.3M | -51.1% |
| Q2 FY2024 | $2.0M | -23.1% | $199.1K | 10.1% |
| Q1 FY2024 | $2.4M | +0.2% | $-103.8K | -4.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.0M | $2.6M | $2.5M | $2.1M | $2.3M | $2.5M | $483760 |
| YoY Growth | 0.2% | -23.1% | 3.0% | 11.0% | -10.3% | 14.5% | -3.3% | -80.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.2M | $11.1M | $11.0M | $10.4M | $9.5M | $9.4M | $7.6M | $9.3M |
| Liabilities | $1.8M | $1.6M | $1.6M | $2.1M | $1.7M | $1.9M | $804966 | $637856 |
| Equity | $9.3M | $9.5M | $9.4M | $8.3M | $7.8M | $7.5M | $6.8M | $8.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-37153 | $-672275 | $-1.6M | $219203 | $-824072 | $-737907 | $-1.2M | $961062 |